biclonal gammopathy

bi·clo·nal gam·mop·a·thy

a gammopathy in which the serum contains two distinct monoclonal immunoglobulins.

biclonal gammopathy

The presence of 2 clonal expansions—IgG > IgA > IgM—in the same patient. Two-thirds of biclonal gammopathies are of undetermined significance; one-third are associated with myeloma or lymphoproliferative disorders, including lymphomas and leukaemias.

biclonal gammopathy

Oncology The presence of 2 clonal expansions–IgG > IgA > IgM, in the same Pt;23 of BGs are of undetermined significance;13 are associated with myeloma or lymphoproliferative disorders, including lymphomas and leukemias. Cf Monoclonal gammopathy of undermined significance.
References in periodicals archive ?
Almost four months after HCT, she developed progressive pancytopenia, biclonal gammopathy, and IGH gene rearrangement.
(1) Biclonal gammopathy, defined as the simultaneous appearance of two different monoclonal protein components, is rare.
Compared to monoclonal gammopathies, reports of biclonal proteins are very few and the finding of biclonal gammopathy in CLL is very rare.
(8) For biclonal gammopathy, the clinical significance and prognostic impact in patients with CLL is uncertain.
A surgical case of solitary plasmacytoma of rib origin with biclonal gammopathy. Jpn J Clin Oncol.
Chronic lymphocytic leukemia with associated lambda-light-chain and IgG lambda paraproteins simulating a biclonal gammopathy. Clin Lab.
Biclonal gammopathy is associated with similar disorders (5) The distribution between various clinical entities, the clinical features of the patients as well as the prognosis seem to be similar to those of monoclonal gammopathies (6).
Pseudotumoral lesions involving the mammary glands, the liver, or the spleen and, recently, glomerulonephritis and cases of monoclonal and biclonal gammopathy have also been associated with B.
Recent work on the development of symptomatic myeloma from biclonal gammopathy of uncertain significance has not shown a greater risk of disease progression, or a poorer response to treatment in those that made progress [4], and there is no evidence to suggest that a different approach to therapy is warranted at the current time in those without evidence of organ damage or presence of high risk biomarkers.
Vallat et al., "IgM Demyelinative neuropathy with amyloidosis and biclonal gammopathy," Annals of Neurology, vol.